| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.25 | 6e-06 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.17 | 1e-05 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0007 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0008 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.001 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.002 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.22 | 0.002 |